Background-The role of programmed ventricular stimulation in identifying patients with Brugada syndrome at the highest risk for sudden death is uncertain. Methods and Results-We performed a systematic review and pooled analysis of prospective, observational studies of patients with Brugada syndrome without a history of sudden cardiac arrest who underwent programmed ventricular stimulation. We estimated incidence rates and relative hazards of cardiac arrest or implantable cardioverter-defibrillator shock. We analyzed individual-level data from 8 studies comprising 1312 patients who experienced 65 cardiac events (median follow-up, 38.3 months). A total of 527 patients were induced into arrhythmias with up to triple extrastimuli. 
B rugada syndrome is a heritable condition marked by ST-segment elevation in the right precordial ECG leads and increased risk of sudden death, typically in individuals without known cardiac disease. 1 Because Brugada syndrome predisposes to ventricular tachyarrhythmias, implantable cardioverter-defibrillators are recommended for individuals with a prior arrest or ventricular arrhythmia. 2 In contrast, risk stratification remains particularly challenging for patients without prior arrests because few develop ventricular arrhythmias and defibrillators may have long-term adverse consequences. 3, 4 Therefore, there is a critical need to accurately identify individuals at increased risk for cardiac arrest, both to minimize morbidity and to maximize efficient resource utilization.
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Since the original description of Brugada syndrome in 1992, 5 invasive programmed ventricular stimulation has been evaluated as a potential tool for stratifying risk and for determining the appropriateness of defibrillator implantation. Some observational studies have supported an association between induced ventricular arrhythmias and subsequent cardiac events, whereas others have not. [6] [7] [8] [9] [10] These studies were of varying size and follow-up, did not necessarily control for known risk factors for cardiac arrest in Brugada syndrome, and often included cardiac arrest survivors in whom a defibrillator would already be indicated for secondary prevention. Consequently, there has been substantial controversy surrounding the utility of programmed stimulation. 11, 12 Existing guidelines neither encourage nor discourage the use of programmed stimulation 2, 13 but state that a defibrillator "may be considered" for patients with induced ventricular arrhythmias during electrophysiology studies. 2 Given the controversial utility of programmed stimulation for patients with Brugada syndrome, we sought to examine the relations between induced ventricular arrhythmias and future events in a multicenter pooled analysis of participant-level data from prospective studies.
Methods Data Sources, Study, and Participant Selection
We searched Embase and Medline for publications on or before August 1, 2012, containing "Brugada syndrome" in the title. We included English articles that involved human subjects who underwent programmed stimulation and excluded case reports. Brugada syndrome was defined as the presence of a type 1 ECG pattern that was present spontaneously or induced by provocation with a sodium channel-blocking drug. We required that studies included at least 10 patients with Brugada syndrome, were prospective, and reported both follow-up duration and number of cardiac events. We excluded studies focused on the investigation of antiarrhythmic drug therapy or studies with overlapping patient populations. We searched references of previous meta-analyses of electrophysiology studies in Brugada syndrome to identify additional articles. [4] [5] [6] Two independent reviewers (S.L. and J.S.) manually reviewed identified abstracts to determine eligible articles for full-text review. Disagreements between reviewers were resolved by consensus. Interrater agreement was high (Cohen κ=0.9).
We then e-mailed the principal authors of identified studies to provide data using a standardized form and definitions. Of the 18 eligible studies identified, 9,10,14-29 principal authors from 8 articles participated, 9, [19] [20] [21] [22] [23] 26, 27 and primary data were no longer accessible for 1 study 14 ( Figure I in the online-only Data Supplement). For the remaining studies, either the authors declined to provide data, or we did not receive responses to our inquiries. The 8 included studies comprised 1364 patients; participant-level data were provided for all. Because additional patients were enrolled and follow-up was extended beyond the publication date in some studies, [20] [21] [22] the numbers of patients in the original publications may differ from those reported here. Follow-up methods in these studies were identical to those reported in the original publications. All included studies required that participants provide written informed consent. The institutional review boards for each respective study approved the protocols.
Of the 1364 individuals identified, we excluded 52 who presented with a cardiac arrest because a defibrillator would be indicated in such individuals regardless of the results of programmed stimulation. We did not exclude patients with a history of syncope. In total, 1312 individuals were included in the analysis.
Definitions of Participant Characteristics, Stimulation Protocols, and Outcomes
We defined participants as asymptomatic if their initial presentation did not include syncope. Of the 8 studies included, 7 studies 9, [19] [20] [21] [22] [23] 27 enrolled only participants with suspected arrhythmogenic syncope on the basis of clinical assessment, whereas 1 study 26 did not differentiate syncope pathogenesis. We defined ECG type 1 patterns as spontaneous or drug induced at the time of enrollment or electrophysiology study in each cohort.
In each cohort, programmed stimulation was performed in accordance with respective study protocols with the intent of determining the prognostic utility of programmed ventricular stimulation. We collected information about the stimulation protocols, including the number of extrastimuli used. We considered ventricular arrhythmia as having been induced if programmed stimulation resulted in either sustained or hemodynamically significant polymorphic ventricular tachycardia or fibrillation.
The primary outcome in this analysis included sudden cardiac arrest or high-voltage defibrillator therapy (ie, shocks) for polymorphic ventricular tachycardia or ventricular fibrillation as determined through defibrillator interrogations during follow-up. Respective cohort investigators reviewed interrogations and adjudicated defibrillator therapy before analysis. To increase the likelihood that the primary outcome consisted of life-threatening arrhythmias, we classified only defibrillator shocks for polymorphic ventricular tachycardia or fibrillation as meeting the primary outcome. In contrast, ventricular arrhythmias terminated by antitachycardia pacing were not classified as meeting the primary outcome. In each cohort, participants were followed up longitudinally according to local protocols.
Statistical Analysis
We estimated survival probabilities free of the primary outcome using the Kaplan-Meier method. We tested differences between strata of interest using the log-rank statistic. We estimated incidence rates and inferred confidence intervals (CIs) using an exact method. We expressed incidence rates as the number of events per 100 personyears or annual percentages for interpretability. Person-time began at programmed stimulation, and individuals were censored at the last follow-up or loss to follow-up.
We assessed the relations between induced ventricular arrhythmias and the primary outcome using multivariable proportional hazards regression. We stratified all models by cohort to adjust for potentially differing baseline hazards in each study. To adhere to the proportional hazards assumption, we also stratified models at the median age value. We introduced age and sex into models to further minimize potential confounding. In additional models, we adjusted for the presence of a spontaneous or drug-induced type 1 Brugada pattern and history of syncope. We verified the proportional hazards assumption by inspecting Schoenfeld residuals.
Because ventricular arrhythmias may be more easily induced but less specific as the number of extrastimuli delivered increases during programmed ventricular stimulation, 30, 31 we also sought to examine by guest on May 21, 2017 http://circ.ahajournals.org/ Downloaded from the relations between the number of extrastimuli resulting in induction and the primary outcome. To determine whether associations between induced arrhythmias and the primary outcome differed by the way in which induced arrhythmia was defined, we varied the definition by designating each individual as having an induced arrhythmia or not with a single extrastimulus, with up to double extrastimuli, and with up to triple extrastimuli. Thus, if an arrhythmia was induced with a single extrastimulus, that individual was also considered to have had an induced arrhythmia if the threshold for induction was modified to include up to double or up to triple extrastimuli. We then tested the association between induced arrhythmias and the primary outcome according to each definition. Next, we regressed the primary outcome on the number of extrastimuli in the protocol that caused induction for each individual by introducing a dummy variable for each potential extrastimulus protocol relative to those who were not induced. To determine the incremental impact of each additional extrastimulus protocol beyond the prior, we performed a similar analysis in which we included an indicator variable for induction and a continuous variable for the number of extrastimuli that enabled assessment for a linear trend in the magnitude of risk associated with the number of extrastimuli causing induction. We then examined associations between each additional extrastimulus protocol and the primary outcome among individuals who were not induced with less aggressive stimulation protocols. Specifically, we assessed induced arrhythmias with double extrastimuli among individuals who were not induced with a single extrastimulus and induced arrhythmias with triple extrastimuli among individuals who were not induced with either single or double extrastimuli. We considered this stratified approach exploratory, given the reduced numbers of participants and events when using it. In secondary analyses, we estimated the adjusted survival probabilities associated with arrhythmia induction using multivariable proportional hazards models.
In sensitivity analyses, we repeated the above modeling after excluding individuals with both a spontaneous type 1 pattern and syncope. All analyses were conducted with R version 3.1.1 32 with the rms 33 and epitools 34 packages. A 2-sided value of P=0.05 was considered statistically significant.
Results
Of the 1312 individuals included, the mean age at electrophysiology study was 44.9±13.3 years, 1034 (79%) were male, 429 (33%) presented with syncope, and 696 (53%) had a spontaneous type 1 ECG pattern ( Table 1 ). The site of ventricular stimulation during electrophysiology study was either the right ventricular apex or outflow tract for all participants. Ventricular arrhythmia were induced with up to double extrastimuli in 253 (19%) of 1312 individuals, and 527 (42%) of 1247 who were tested with up to triple extrastimuli (65 individuals who were not induced with single or double extrastimuli were not tested with triple extrastimuli). Defibrillators were implanted in 576 patients (44%), and 18 patients (1.4%) received an implantable loop recorder. Defibrillator implantation was more common in patients with induced arrhythmias (defined as up to double extrastimuli; n=196, 77%) than in those without (n=380, 36%). Either antiarrhythmic drugs were not used, or their use was not tracked in most patients (see Results in the online-only Data Supplement).
During a median follow-up of 38.3 months (interquartile range, 20.9-60.3 months), 65 patients (5%) experienced a sudden cardiac arrest (n=5) or received an appropriate defibrillator shock (n=60), corresponding to an annual incidence rate (Table 3) . Arrhythmias induced with a single extrastimulus were not significantly associated with future events 20) . However, the number of individuals induced was small (n=22), and the effect was in the same direction as in analyses of up to double and triple extrastimuli, suggesting limited power in the single extrastimulus analysis. The magnitudes of effect did not differ substantively between models adjusted for cohort, age, and sex only compared with more extensively adjusted models including syncope history and ECG pattern. Syncope on presentation and spontaneous type 1 ECG patterns remained significantly associated with the primary outcome in adjusted models (Table I in the online-only Data Supplement).
To assess the incremental utility of each additional extrastimulus protocol, we regressed the primary outcome on the number of extrastimuli in the protocol that caused arrhythmia induction, comparing associations between those with and without induced arrhythmias (Table 4 and Figure 2 ). The risk of events appeared greatest among individuals induced with single or double extrastimuli. In exploratory analyses, we examined the incremental utility of each additional extrastimulus protocol in strata of individuals not induced with less aggressive protocols (Table II in the online-only Data Supplement). Among the 1312 individuals, 22 (2%) were induced with a single extrastimulus. In the remaining 1290 individuals not induced with a single extrastimulus, induction with double extrastimuli (n=231, 18%) was associated with the primary outcome (HR, 2.55; 95% CI, 1.34-4.88; P=0.005). In contrast, among the 994 individuals who were not induced with single or double extrastimuli, induction with triple extrastimuli (n=274, 28%) was less specific (HR, 2.08; 95% CI, 0.98-4.39; P=0.06). The estimated survival free of events stratified by induction with up to double extrastimuli and for incremental triple extrastimuli among those not induced with up to double stimuli is displayed in Figure II in the online-only Data Supplement. No substantive differences in the above models were observed in sensitivity analyses excluding patients with a spontaneous type 1 pattern and syncope (Table 5 and Table  II in the online-only Data Supplement). Specifically, induced arrhythmias remained significantly associated with arrhythmia despite a smaller sample and fewer events.
Annual event rates were considerable both among those with induced arrhythmias (2.32%, 95% CI, 1.50-3.41 for up to double extrastimuli; 1.99%, 95% CI, 1.43-2.72 for up to triple extrastimuli) and those without induced arrhythmias (1.05%, 95% CI, 0.75-1.43 for up to double extrastimuli; 0.94%, 95% CI, 0.61-1.39 for up to triple extrastimuli) but varied substantially by syncope history and ECG pattern in exploratory analyses (Table 2 and Table III in the online-only Data Supplement). Given the increased specificity of less aggressive stimulation protocols, we plotted survival probabilities according to the presence or absence of induction, considering induction as that occurring with either single or double extrastimuli (Figure 3 ).
Discussion
In this multicenter, pooled analysis of 1312 patients with Brugada syndrome without prior cardiac arrest, ventricular Comparison of prior literature addressing electrophysiology studies for risk stratification in Brugada syndrome is challenging owing to differences in follow-up duration, inclusion of patients with prior cardiac arrest who are at significantly elevated risk for recurrent events, and adjustment for clinical predictors of cardiac arrest.
9,10,14-26,28,29 Furthermore, some studies were small, limiting power to detect associations. By pooling participant-level data from several cohorts, we were able to enhance power, to maximize observed follow-up, and to adjust for accepted risk factors.
Our findings support and extend prior observations on the longitudinal history of Brugada syndrome. We observed an expected risk gradient, 2 with the highest incidence of events occurring in patients with syncope and spontaneous type 1 patterns. The lowest risk occurred in asymptomatic patients with drug-induced type 1 ECG patterns. Arrhythmia induction during programmed stimulation was associated with future events despite multivariable adjustment for syncope and ECG pattern. Specificity of induction appeared to decrease as the number of extrastimuli associated with arrhythmia induction increased, consistent with other cardiac diseases such as ischemic cardiomyopathy. 30, 31 Indeed, about one fifth of individuals were induced with either single or double extrastimuli, whereas nearly one third who were not were induced with triple extrastimuli.
Our study has 3 main implications for risk stratification of patients with Brugada syndrome. First, our results suggest that arrhythmia induction with moderately aggressive stimulation protocols may identify patients with Brugada syndrome without prior cardiac arrest who are at increased risk for sudden cardiac death but that triple extrastimuli are nonspecific Analysis includes 1247 individuals in whom ventricular arrhythmias were induced or testing was carried forward to triple extrastimuli. CI indicates confidence interval; and HR, hazard ratio. *The linear model was fit by including terms for both the presence of arrhythmia induction and the number of extrastimuli in the protocol causing induction. Figure 2 . Risk of sudden cardiac arrest or ventricular tachycardia resulting in defibrillator shock relative to individuals who were not induced is displayed according to the number of extrastimuli in the protocol associated with induction. The hazard ratios for each extrastimulus protocol (black points and 95% confidence bars) relative to those who were not induced are displayed. Superimposed are the association and 95% confidence interval (gray) derived from a model composed of both an indicator for induction and linear term for the number of extrastimuli causing induction on the basis of the effect estimates and covariance between both terms. Estimates were derived from models including the 1247 individuals in whom ventricular arrhythmias were induced or testing was carried forward to triple extrastimuli. Models were adjusted for age at electrophysiology study, sex, syncope, and spontaneous type 1 Brugada pattern. and therefore of limited clinical utility. Our observations are consistent with a prior single-center study in an independent group of 108 patients by Makimoto et al. 28 Thus, in patients with Brugada syndrome undergoing electrophysiology study, we submit that programmed ventricular stimulation is most informative when limited to protocols including up to double extrastimuli.
Second, lack of induction with programmed stimulation alone does not reliably identify low-risk patients. Consideration of clinical risk factors that determine the pretest probability of cardiac arrest may help establish the utility of programmed stimulation, although in many situations clinical challenges remain. For example, in asymptomatic patients with spontaneous type 1 ECG patterns, considerable risk of arrhythmia may persist even among those in whom arrhythmias are not induced. In contrast, asymptomatic patients with drug-induced ECG patterns are at low risk. In such patients, programmed stimulation may not be warranted, considering the low likelihood of cardiac arrest, imperfect nature of programmed stimulation to predict events, and lack of indication for a defibrillator 2 in this subgroup. Similarly, individuals with a spontaneous type 1 pattern and a high index of suspicion for arrhythmogenic syncope are at high risk, 35, 36 and lack of arrhythmia induction may not lower the probability of cardiac arrest sufficiently to obviate the indication for a defibrillator. 2, 13 Future guidelines may address the appropriate risk thresholds for using electrophysiology studies in patients with Brugada syndrome.
Third, the substantial risk of events observed among individuals with syncope in our analysis likely reflects the fact that ours is enriched for patients with arrhythmogenic syncope. Our results underscore the importance of distinguishing arrhythmogenic from nonarrhythmogenic syncope in clinical settings, particularly given the increased frequency of vasovagal syncope reported in patients with Brugada syndrome. 22, 37 Our study should be interpreted in the context of the observational study design. Specifically, we cannot exclude that defibrillator shocks were mediated by overdiagnosis of ventricular arrhythmias by defibrillators, given the nonrandomized study designs, the likelihood that patients who were induced were more likely to receive implantable defibrillators, and the potential for less contemporary programmed defibrillator therapy settings. 38 Indeed, the majority of observed events in our analysis were implantable cardioverter-defibrillator therapies rather than cardiac arrests. Therefore, we submit that future studies should use randomization or implantation of loop recorders in individuals who do not receive defibrillators. We acknowledge the potential for residual confounding, despite adjustment for clinically relevant risk factors such as age, sex, presenting ECG pattern, and syncope history. In particular, features such as ECG pattern or syncope history may change over time. We did not address the impact of antipyretics, sodium channel-blocking drug avoidance, or antiarrhythmic drug use on outcomes. Studies may have enrolled high-risk patients to undergo electrophysiology study, and our findings therefore may not be generalizable to all patients with Brugada syndrome. Our analysis did not address some electrophysiological features that may have prognostic value, including the HV interval, 5 effective ventricular refractory period, 9 minimum coupling interval, or ventricular site of induction. 39 Arrhythmia induction may not be reproducible with repeated attempts, potentially limiting the reliability of the technique. 9 As with most studies of Brugada syndrome, follow-up remains limited to several years despite data pooling. Incidence rates are based on the assumption that event risks are constant over time. We had limited power to precisely estimate event risks in groups stratified by syncope history, presenting ECG pattern, and induction with programmed stimulation. Furthermore, we had limited power to test for a linear relation between the number of extrastimuli causing induction and risk of events.
Conclusions
Programmed stimulation may identify patients with Brugada syndrome at increased risk for cardiac arrest, but the association appears most apparent in individuals induced with single or double extrastimuli rather than more aggressive stimulation protocols. Importantly, the absence of induction with programmed stimulation alone is not sufficient to identify low-risk individuals. We submit that electrophysiology studies in patients with Brugada syndrome are reasonable but that the decision to proceed should be individualized after clinical risk stratification and detailed counseling with patients about the implications of a positive or negative result. Future efforts to improve risk stratification, to identify prophylactic measures, and to assess long-term riskbenefit tradeoffs of interventions in patients with Brugada syndrome without prior cardiac arrest are warranted. Although potentially challenging, high-quality prospective studies such as randomized trials are warranted for patients with Brugada syndrome.
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CLINICAL PERSPECTIVE
Brugada syndrome is associated with increased risk for sudden cardiac death. However, the risk distribution is not uniform among patients with Brugada syndrome, and most do not experience adverse cardiac events during their lives. Identification of those at greatest risk who would benefit from implantable cardiac defibrillators poses a major clinical challenge. Programmed ventricular stimulation (PVS) has been proposed as a method to facilitate risk stratification of patients with Brugada syndrome, but controversy surrounding the utility of PVS has persisted for the past 2 decades. Our pooled analysis of individual-level data from 8 studies and ≈1300 patients with Brugada syndrome suggests that induced ventricular arrhythmias during PVS are associated with a higher risk of cardiac events. However, our observations also show that lack of induced arrhythmia during PVS is not necessarily synonymous with low risk. These findings underscore the importance of risk stratification using clinical features such as spontaneous type 1 electrocardiogram patterns and syncope, which facilitate identification of individuals at highest and lowest risk of events in whom PVS may be of limited utility. Furthermore, our study highlights the importance of using appropriate PVS protocols because moderately aggressive protocols (eg, up to double extrastimuli) appear to yield higher specificity for adverse outcomes than more aggressive PVS protocols (eg, up to triple extrastimuli). Taken together, our data suggest that PVS may have a role in the assessment of select patients with Brugada syndrome with intermediate clinical risk of events but that negative electrophysiological studies should not be considered indicative of low risk of cardiac events. Future prospective studies are needed to improve risk-stratification tools. 
